Clinical trial
Peroral Levosimendan in Chronic Heart Failure
NCT00130884 · Orion Corporation, Orion Pharma, Industry · Completed
Key facts
| NCT number | NCT00130884 |
|---|---|
| Title | Peroral Levosimendan in Chronic Heart Failure |
| Official title | Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure. A Randomised, Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study |
| Lead sponsor | Orion Corporation, Orion Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Heart Failure, Heart Diseases |
| Intervention type | Drug |
| Interventions | levosimendan |
| Enrollment | 300 |
| Start date | Mar 1, 2005 |
| Completion | Mar 1, 2006 |
| First posted | Aug 16, 2005 |
| Last update posted | Feb 21, 2007 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: